SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

Bexsero

GSK·GSK plc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (US since 2015, EU since 2013). The booster label expansion for ages 10+ is under EMA review with a positive CHMP opinion; European Commission decision expected within 1-2 months.
Why 4/10
The next catalyst is the European Commission's decision on the booster label expansion, which typically follows the CHMP positive opinion (received November 13, 2026) within 1-2 months. However, Bexsero is an already-approved, marketed product at a large diversified pharma company (GSK), so this label expansion is a modest commercial event, not a binary approval catalyst.
Actionable Insight NEUTRAL

The CHMP recommended Bexsero's label expansion for a single booster dose on November 13, 2026. The European Commission typically follows CHMP recommendations within 1-2 months, which would be the next catalyst. If approved, this expands the addressable adolescent/young adult booster market in Europe. Separately, Bexsero is being studied for cross-protection against gonorrhea, a potential long-term value driver, but no pivotal readout is scheduled.

Price Chart

Loading chart...

Executive Summary

Bexsero is GSK's approved meningococcal group B (MenB) vaccine, first authorized in Europe in 2013 and the US in January 2015. It is a marketed product facing competition from Pfizer's Trumenba and increasingly from GSK's own broader 5-in-1 meningococcal vaccine PENMENVY (approved 2025). On November 13, 2026, GSK announced a positive CHMP opinion recommending a label expansion for a single booster dose in ages 10+, based on Phase IIIb data. The European Commission decision (expected within 1-2 months) is the next catalyst. Bexsero is also being studied for cross-protection against gonorrhea, a potential long-term opportunity. For a large diversified pharma like GSK, Bexsero is one of many products; the booster label expansion is a modest commercial event rather than a stock-moving binary.

How It Works

Bexsero is a vaccine that trains the immune system to recognize and fight Neisseria meningitidis serogroup B bacteria, which can cause meningitis and bloodstream infections. It contains four components: three lab-made proteins found on the surface of MenB bacteria (NadA, fHbp, NHBA) plus outer membrane vesicles from a MenB strain. When injected, the body produces antibodies against these components, providing protection if the person is later exposed to the bacteria.

Trial Status

Bexsero is an approved, marketed vaccine. A Phase IIIb study (Men-B-096) evaluating a single booster dose in healthy individuals aged 10-20 years supported the recent positive CHMP opinion for label expansion. Additional Phase II research is exploring cross-protection against gonorrhea. Multiple completed Phase 3 studies have evaluated Bexsero's safety and immunogenicity in infants and children.

The Two-Sided Case

▲ Bull Case4
Bexsero is a well-established, approved vaccine with a strong safety/efficacy profile and is the leading MenB vaccine in many markets. It was first approved in Europe in 2013 and the US in 2015.
On November 13, 2026, the EMA's CHMP recommended updating Bexsero's label to include a single booster dose for ages 10+, based on positive Phase IIIb data (Men-B-096 study), which could expand the addressable market as the first vaccinated cohort reaches adolescence.
Bexsero is being studied for cross-protection against gonorrhea (Phase II data published November 2026 showed it generates antibodies against gonorrhea antigens), which could open a much larger public health market if confirmed.
A UK meningococcal outbreak in Kent in early 2026 has raised awareness and could drive expanded MenB vaccination schedules, benefiting Bexsero.
▼ Bear Case4
Bexsero faces direct competition from Pfizer's Trumenba (also a MenB vaccine), which won EU approval in 2017 and competes in the same market.
GSK's own PENMENVY (5-in-1 meningococcal vaccine, approved 2025) covers serogroup B plus A, C, W, and Y in one shot, potentially cannibalizing Bexsero's market for patients wanting broader coverage.
GSK's overall vaccines segment underperformed in Q3 2026, with soft vaccine sales dragging the stock despite an earnings beat, suggesting headwinds for the entire vaccines portfolio.
Jefferies downgraded GSK from Buy to Hold in October 2026, reflecting concerns about pipeline and vaccine growth.

Upcoming Catalysts

  • European Commission decision on Bexsero booster label expansion for ages 10+ (expected within 1-2 months following November 13, 2026 CHMP positive opinion)
  • Potential UK schedule expansion following the 2026 Kent meningococcal outbreak
  • Ongoing research on Bexsero's cross-protection against gonorrhea (early-stage, no pivotal readout scheduled)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 9

Hover a chip for the title
1 theglobeandmail.com2 rttnews.com3 marketscreener.com4 marketscreener.com5 bioengineer.org6 msn.com7 msn.com8 fiercepharma.com9 businesswire.com